 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...1718192021222324252627...3334» |
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Stivarga (regorafenib) / Bayer
Journal: How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. (Pubmed Central) - Apr 21, 2021
Telemedicine permits the remote management of patients who are receiving oral therapies. Many of these strategies will likely remain in place after the pandemic ends.
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Apr 18, 2021
P3, N=434, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Many of these strategies will likely remain in place after the pandemic ends. Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Mar 2024
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Avastin (bevacizumab) / Roche
Clinical, P2 data, Clinical Trial,Phase II, Journal: Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer. (Pubmed Central) - Apr 14, 2021
Biweekly TAS-102 plus bevacizumab facilitates tumor shrinkage by reducing the incidence of grade 3 or more neutropenia, improving survival, and maintaining performance status. This combination may represent a treatment option for patients with late-stage mCRC receiving third- or later-line therapy.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Stivarga (regorafenib) / Bayer
Clinical, Clinical data, Retrospective data, Journal: Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment. (Pubmed Central) - Apr 14, 2021
This combination may represent a treatment option for patients with late-stage mCRC receiving third- or later-line therapy. Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib.
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Stivarga (regorafenib) / Bayer
.@GIcancerDoc, of @MayoClinic, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer #crcsm https://t.co/12YpRbqArO (Twitter) - Apr 11, 2021
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Avastin (bevacizumab) / Roche
Combination therapy: .@agrothey, of @west_cancer, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer #crcsm https://t.co/lLrz5P2DZX (Twitter) - Apr 10, 2021
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Avastin (bevacizumab) / Roche
Clinical, Journal: Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab (Pubmed Central) - Apr 9, 2021
The patient received several courses of chemotherapy with adjustments of the dose and dosing intervals to prevent neutropenia. Combination therapy using TAS-102 and bevacizumab is a feasible Late-line chemotherapeutic regimen for colorectal cancer.
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Metastases: TACTIC: Trifluridin/tipirACil in meTastatIc Colorectal Cancer (clinicaltrials.gov) - Apr 2, 2021
P=N/A, N=315, Active, not recruiting, Sponsor: Servier Deutschland GmbH
Combination therapy using TAS-102 and bevacizumab is a feasible Late-line chemotherapeutic regimen for colorectal cancer. Recruiting --> Active, not recruiting
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] ASK THE INVESTIGATORS: APPLYING EMERGING CLINICAL RESEARCH TO THE CARE OF PATIENTS WITH GASTROESOPHAGEAL CANCERS () - Mar 28, 2021 - Abstract #AACR2021AACR_5257;
Appreciate the recent FDA approvals of pembrolizumab and nivolumab for previously treated squamous cell carcinoma of the esophagus, and identify patients appropriate for treatment with these agents...Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. Supporters This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Five Prime Therapeutics Inc.
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
.@GIcancerDoc, of @MayoClinic, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer #crcsm https://t.co/IlISgFGhiw (Twitter) - Mar 27, 2021
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Combination therapy: .@agrothey, of @west_cancer, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer #crcsm https://t.co/GdnvRPZ3uF (Twitter) - Mar 26, 2021
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays. (Pubmed Central) - Mar 26, 2021
P1/2
The strong radiosensitising effect observed in vitro after prolonged treatment with FTD/TPI and equivalence with capecitabine-based chemoradiation in vivo support a daily fractionated combined regime of FTD/TPI and radiation in rectal cancer treatment. This is now being tested in a phase I/II clinical trial (NCT04177602).
- || Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
Trial completion, Enrollment change, Combination therapy, Metastases: REMETY: Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy (clinicaltrials.gov) - Mar 26, 2021
P1, N=12, Completed, Sponsor: AIO-Studien-gGmbH
This is now being tested in a phase I/II clinical trial (NCT04177602). Recruiting --> Completed | N=18 --> 12
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Clinical, Observational data, Journal: Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). (Pubmed Central) - Mar 26, 2021
Subgroup analysis adjusted using multivariate Cox model revealed a consistently better trend in most subgroups for cohort A compared with cohort B. Our study revealed prolonged survival in patients treated with REG and TFTD. Therefore, all active agents, including REG and TFTD, should be made available to mCRC patients.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal: Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. (Pubmed Central) - Mar 25, 2021
Therefore, all active agents, including REG and TFTD, should be made available to mCRC patients. Irinotecan plus cetuximab rechallenge as third-line treatment for KRAS wild-type mCRC was safe and had promising activity, especially in those with a long CFI, warranting further investigation in a Phase 3 randomised trial.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Surgery, Metastases: TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 23, 2021
P1, N=7, Active, not recruiting, Sponsor: Mayo Clinic
Irinotecan plus cetuximab rechallenge as third-line treatment for KRAS wild-type mCRC was safe and had promising activity, especially in those with a long CFI, warranting further investigation in a Phase 3 randomised trial. Trial completion date: Mar 2021 --> Mar 2022
- | Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial, Metastases: iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Mar 21, 2021
P2, N=20, Not yet recruiting, Sponsor: AHS Cancer Control Alberta
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Video: VIDEO: Impact of prior therapies on outcomes with trifluridine/tipiracil w/ @KoheiShitara of National Cancer Center Hospital East 👉https://t.co/HkSh4fTIrG👈 @VJOncology @OncoAlert @ASCO #GI21 #GIsm #STCsm #GastricCancer #StomachCancer #OncoAlert #Oncology #ClinOnc #MedOnc (Twitter) - Mar 18, 2021
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Combination therapy: .@agrothey, of @west_cancer, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer #crcsm https://t.co/EBDncAjm67 (Twitter) - Mar 17, 2021
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
.@GIcancerDoc, of @MayoClinic, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer #crcsm https://t.co/3tFBQEn2T8 (Twitter) - Mar 17, 2021
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Talzenna (talazoparib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (clinicaltrials.gov) - Mar 16, 2021
P1, N=21, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Mar 2021 --> Mar 2022 Trial completion date: Mar 2023 --> Apr 2024 | Trial primary completion date: Mar 2022 --> Apr 2023
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
.@GIcancerDoc, of @MayoClinic, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer #crcsm https://t.co/EVqdAoTvfy (Twitter) - Mar 14, 2021
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Combination therapy: .@agrothey, of @west_cancer, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer #crcsm https://t.co/HPHpgpfZys (Twitter) - Mar 14, 2021
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal, HEOR, Real-World Evidence: Quality of Life in a Real-World Study of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil. (Pubmed Central) - Mar 12, 2021
No significant differences for pain were observed between the groups. This study suggests that ftd/tpi is a well-tolerated option for the treatment of patients with refractory mcrc, showcasing the value of capturing real-world qol data in routine clinical practice.
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Clinical, Reimbursement: My morning-“The insurance company has denied your request for lonsurf because you haven’t tried cetuximab or panitumumab for right sided kras mutant metastatic CRC in 30-something year old patient” clearly documented in the note. yup #MedTwitter #oncology2021 (Twitter) - Mar 9, 2021
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Here you go ...everything about TAS-102...served!@Amitmahipal79 @CCA_Alliance @IHPBA https://t.co/G004JTiwEo (Twitter) - Mar 8, 2021
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly
Clinical, P2 data, Clinical Trial,Phase II, Journal: Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. (Pubmed Central) - Mar 6, 2021
This study suggests that ftd/tpi is a well-tolerated option for the treatment of patients with refractory mcrc, showcasing the value of capturing real-world qol data in routine clinical practice. Trifluridine/tipiracil and ramucirumab showed an acceptable safety profile and clinical activity in patients with previously treated advanced gastric cancer regardless of previous ramucirumab exposure.
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical: So if a clinical trial was unavailable, you would go straight to rego or lonsurf for 3rd line? (Twitter) - Mar 3, 2021
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
[VIRTUAL] Regorafenib for advanced colorectal cancer who previously received by trifluridine/tipiracil plus bevacizumab () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1126;
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Efficacy and Eligibility Predictors of Trifluridine/Tipiracil Biweekly Regimen in Advanced Colorectal Cancer () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1123;
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Trifluridine/tipiracil [Ron] and irinotecan [IRI] for advanced gastric cancer refractory to third-line nivolumab [Nivo] () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1111;
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer (Track 7) - Mar 2, 2021 - Abstract #JSMO2021JSMO_878;
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Safety and efficacy of trifluridine/tipiracil administered after anti-PD-1 therapies for advanced gastric cancer (Track 12) - Mar 2, 2021 - Abstract #JSMO2021JSMO_87;
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly
Journal: Trifluridine/tipiracil plus ramucirumab in gastric cancer. (Pubmed Central) - Mar 2, 2021
Trifluridine/tipiracil and ramucirumab showed an acceptable safety profile and clinical activity in patients with previously treated advanced gastric cancer regardless of previous ramucirumab exposure. No abstract available
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Feb 28, 2021
P3, N=434, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical: Does Lonsurf have a response rate of just 1.6%? sorry does it mean that only 1, 6% of patients work? Is there a drug for colon cancer mestatisco in tests in the world? (Twitter) - Feb 24, 2021
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical: Another paper supports elderly patient's access to effective treatment. Geriatric Assessment is the key!. Last year we had the PANDA study support 5fu+ipi, and this year, we saw the abstract of lonsurf + Avastin for those who can't tolerate more aggressive treatment. (Twitter) - Feb 22, 2021
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical, Journal: A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment (Pubmed Central) - Feb 20, 2021
She has been taking mFOLFOX6 with bevacizumab (80%)as a second-line treatment. TFTD with bevacizumab treatment was safe and efficacious as a first-line treatment for a frail elderly patient with unresectable colorectal cancer.
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Trial completion date, Trial primary completion date: Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases (clinicaltrials.gov) - Feb 18, 2021
P1, N=21, Active, not recruiting, Sponsor: University of California, San Francisco
TFTD with bevacizumab treatment was safe and efficacious as a first-line treatment for a frail elderly patient with unresectable colorectal cancer. Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Feb 2025 | Trial primary completion date: Aug 2024 --> Feb 2025
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Retrospective data, Journal: Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. (Pubmed Central) - Feb 18, 2021
FTD/TPI plus BEV prolonged PFS and OS and had tolerable toxicity compared with FTD/TPI alone. CIN is an indicator of patients who will benefit from FTD/TPI plus BEV.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal: Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. (Pubmed Central) - Feb 16, 2021
CIN is an indicator of patients who will benefit from FTD/TPI plus BEV. These results indicate that FTD persists longer in tumors than in bone marrow, which may cause a sustained antitumor effect with tolerable hematotoxicity.
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical: So, re ☝🏻, outside of clinical trials & in your hypothetical scenario: 1L FOLFOX-tras 2L pac-ram 3L FOLFIRI 4L?? w PS 0 I let biology do the talking: If HER2+ dz resurging: TDXd (or other antiHer2 strategy) If still HER2-: TAS-102. (As in your hypothetical scenario) (Twitter) - Feb 9, 2021
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
HEOR: DPYD genotyping appears to be cost-effective in the US setting - which would make it more cost-effective than many of the interventions that we routinely use (e.g. regorafenib, trifluridine/tipiracil, bev after progression...) https://t.co/JwFkOwO2wb (Twitter) - Feb 9, 2021
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Journal, HEOR: Comparative Cost-Utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. (Pubmed Central) - Feb 9, 2021
As a third-line or later treatment of metastatic colorectal cancer in Japan, T/T is cost-effective compared with BSC, whereas regorafenib is not. It is necessary to adjust the price of regorafenib based on the results of this analysis, with the improvement of clinical parameters such as survival time and adverse events.
- || irinotecan / Generic mfg.
Clinical, Journal, Checkpoint inhibition, BRCA Biomarker, IO biomarker: Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. (Pubmed Central) - Feb 9, 2021
The results of this small cohort need to be validated in independent prospective cohorts. The role of ICIs as modifiers of both tumour cells and microenvironment in mCRC deserves further research.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Retrospective data, Journal: Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis. (Pubmed Central) - Feb 9, 2021
The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
#NationalComprehensiveCancerNetwork® Provides Updates on Use of #LONSURF® (#Trifluridine and #Tipiracil) in NCCN Drugs and Biologics #Compendium® for #ColonCancer and #RectalCancer https://t.co/HaTQoh1UhL (Twitter) - Feb 5, 2021
- Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date, Metastases: TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) (clinicaltrials.gov) - Feb 4, 2021
P2, N=7, Terminated, Sponsor: University of Florida
Further study is required to determine appropriate treatment choice. Trial primary completion date: Jan 2020 --> Jul 2020
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Dr Eng, I was referring to the PFS of 9.2 vs 7.8. The OS of 22.3 vs 17.7 looks better. Any opinion on TAS-102 w/ Bev vs Folfiri w/ Bev? (Twitter) - Feb 3, 2021
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka
New P3 trial, Combination therapy, Monotherapy, Metastases: SUNLIGHT: Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Feb 2, 2021
P3, N=490, Recruiting, Sponsor: Taiho Oncology, Inc.